U.S. approves Eisai and Biogen’s drug to slow Alzheimer’s disease – The Japan Times

U.S. approves Eisai and Biogen’s drug to slow Alzheimer’s disease – The Japan Times

Read Time:7 Second

In a landmark decision, the FDA says the benefits of aducanumab, a controversial therapy designed to inhibit cognitive decline, outweigh the risks.Read More

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published.